Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06407232 · ClinicalTrials.gov registry record · Phase 3
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
A Phase 3 study of Cytomegalovirus Infections and Kidney Transplant Infection, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06407232 is a Phase 3 study of Cytomegalovirus Infections and Kidney Transplant Infection that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 90 participants, below the 199-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06407232, a Phase 3 study of Cytomegalovirus Infections and Kidney Transplant Infection, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (1)
Wisconsin
- UW Hospital and Clinics - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06407232
The ClinicalTrials.gov registry entry for NCT06407232 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (55% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which Letermovir is the first listed.
NCT06407232 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06407232 about?
NCT06407232 is a clinical study titled "Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients". This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
What is the current status of trial NCT06407232?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2024-08-08. Estimated completion is 2026-09.
What conditions does trial NCT06407232 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant.
What interventions are being tested in trial NCT06407232?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT06407232?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06407232 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
COMPLETED · Phase 3
-
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
COMPLETED · Phase 3
-
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
COMPLETED · Phase 3
-
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
COMPLETED · Phase 3
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.